Top

Published in:

Open Access 01-04-2020 | Nephrectomy | Research Paper

Curative-intent pancreas resection for pancreatic metastases: surgical and oncological results

Authors: Sophia Chikhladze, Ann-Kathrin Lederer, Christian M. Kühlbrey, Julian Hipp, Olivia Sick, Stefan Fichtner-Feigl, Uwe A. Wittel

Published in: Clinical & Experimental Metastasis | Issue 2/2020

Abstract

Background

Pancreatic metastasis is a rare cause for pancreas surgery and often a sign of advanced disease no chance of curative-intent treatment. However, surgery for metastasis might be a promising approach to improve patients’ survival. The aim of this study was to analyze the surgical and oncological outcome after pancreatic resection of pancreatic metastasis.

Methods

This is a retrospective cohort analysis of a prospectively-managed database of patients undergoing pancreatic resection at the University of Freiburg Pancreatic Center from 2005 to 2017.

Results

In total, 29 of 1297 (2%) patients underwent pancreatic resection due to pancreatic metastasis. 20 (69%) patients showed metastasis of renal cell carcinoma (mRCC), followed by metastasis of melanoma (n = 5, 17%), colon cancer (n = 2, 7%), ovarian cancer (n = 1, 3%) and neuroendocrine tumor of small intestine (n = 1, 3%). Two (7%) patients died perioperatively. Median follow-up was 76.4 (range 21–132) months. 5-year and overall survival rates were 82% (mRCC 89% vs. non-mRCC 67%) and 70% (mRCC 78% vs. non-mRCC 57%), respectively. Patients with mRCC had shorter disease-free survival (14 vs. 22 months) than patients with other primary tumor entities.

Conclusion

Despite malignant disease, overall survival of patients after metastasectomy for pancreatic metastasis is acceptable. Better survival appears to be associated with the primary tumor entity. Further research should focus on molecular markers to elucidate the mechanisms of pancreatic metastasis to choose the suitable therapeutic approach for the individual patient.

Sperti C, Moletta L, Patanè G (2014) Metastatic tumors to the pancreas: the role of surgery. World J Gastrointest Oncol 6:381–392. https://doi.org/10.4251/wjgo.v6.i10.381 CrossRefPubMedPubMedCentral

Sperti C, Pasquali C, Liessi G et al (2003) Pancreatic resection for metastatic tumors to the pancreas. J Surg Oncol 83:161–166. https://doi.org/10.1002/jso.10262 CrossRefPubMed

Niess H, Conrad C, Kleespies A et al (2013) Surgery for metastasis to the pancreas: is it safe and effective? J Surg Oncol 107:859–864. https://doi.org/10.1002/jso.23333 CrossRefPubMed

Stankard CE, Karl RC (1992) The treatment of isolated pancreatic metastases from renal cell carcinoma: a surgical review. Am J Gastroenterol 87:1658–1660PubMed

Nakamura E, Shimizu M, Itoh T, Manabe T (2001) Secondary tumors of the pancreas: clinicopathological study of 103 autopsy cases of Japanese patients. Pathol Int 51:686–690CrossRefPubMed

Strobel O, Buechler MW (2015) Pancreatic metastases from tumors in the urogenital tract. Gastrointest Tumors 2:75–82. https://doi.org/10.1159/000431045 CrossRefPubMedPubMedCentral

Strobel O, Hackert T, Hartwig W et al (2009) Survival data justifies resection for pancreatic metastases. Ann Surg Oncol 16:3340–3349. https://doi.org/10.1245/s10434-009-0682-3 CrossRefPubMed

Masetti M, Zanini N, Martuzzi F et al (2010) Analysis of prognostic factors in metastatic tumors of the pancreas: a single-center experience and review of the literature. Pancreas 39:135–143. https://doi.org/10.1097/MPA.0b013e3181bae9b3 CrossRefPubMed

Tosoian JJ, Cameron JL, Allaf ME et al (2014) Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital. J Gastrointest Surg 18:542–548. https://doi.org/10.1007/s11605-013-2278-2 CrossRefPubMed

10.

Sellner F, Tykalsky N, De Santis M et al (2006) Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 13:75–85. https://doi.org/10.1245/ASO.2006.03.064 CrossRefPubMed

11.

Adler H, Redmond CE, Heneghan HM et al (2014) Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol 40:379–386. https://doi.org/10.1016/j.ejso.2013.12.022 CrossRefPubMed

12.

Sperti C, Pozza G, Brazzale AR et al (2016) Metastatic tumors to the pancreas: a systematic review and meta-analysis. Minerva Chir 71:337–344PubMed

13.

Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 161:584–591. https://doi.org/10.1016/j.surg.2016.11.014 CrossRefPubMed

14.

Wente MN, Veit JA, Bassi C et al (2007) Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition. Surgery 142:20–25. https://doi.org/10.1016/j.surg.2007.02.001 CrossRefPubMed

15.

Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142:761–768. https://doi.org/10.1016/j.surg.2007.05.005 CrossRefPubMed

16.

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae CrossRefPubMedPubMedCentral

17.

Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2 CrossRefPubMed

18.

Reddy S, Edil BH, Cameron JL et al (2008) Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol 15:3199–3206. https://doi.org/10.1245/s10434-008-0140-7 CrossRefPubMed

19.

Dong J, Cong L, Zhang T-P, Zhao Y-P (2016) Pancreatic metastasis of renal cell carcinoma. Hepatobiliary Pancreat Dis Int 15:30–38. https://doi.org/10.1016/S1499-3872(16)60052-8 CrossRefPubMed

20.

Zerbi A, Ortolano E, Balzano G et al (2008) Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol 15:1161–1168. https://doi.org/10.1245/s10434-007-9782-0 CrossRefPubMed

21.

Untch BR, Allen PJ (2014) Pancreatic metastasectomy: the memorial sloan-kettering experience and a review of the literature. J Surg Oncol 109:28–30. https://doi.org/10.1002/jso.23460 CrossRefPubMed

22.

Pedrazzoli S (2017) Pancreatoduodenectomy (PD) and postoperative pancreatic fistula (POPF). Medicine (Baltimore) 96:e6858. https://doi.org/10.1097/MD.0000000000006858 CrossRef

23.

Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13. https://doi.org/10.1016/j.surg.2005.05.001 CrossRefPubMed

24.

Wellner UF, Keck T (2017) Quality indicators in pancreatic surgery: lessons learned from the German DGAV StuDoQ|pancreas registry. Visc Med 33:126–130. https://doi.org/10.1159/000456045 CrossRefPubMedPubMedCentral

25.

Ho C, Kleeff J, Friess H, Büchler MW (2005) Complications of pancreatic surgery. HPB 7:99–108. https://doi.org/10.1080/13651820510028936 CrossRefPubMedPubMedCentral

26.

Peng Y-P, Zhu X-L, Yin L-D et al (2017) Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. Sci Rep 7:185. https://doi.org/10.1038/s41598-017-00311-8 CrossRefPubMedPubMedCentral

27.

McMillan MT, Christein JD, Callery MP et al (2016) Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy. Surgery 159:1013–1022. https://doi.org/10.1016/j.surg.2015.10.028 CrossRefPubMed

28.

Hu B-Y, Wan T, Zhang W-Z, Dong J-H (2016) Risk factors for postoperative pancreatic fistula: analysis of 539 successive cases of pancreaticoduodenectomy. World J Gastroenterol 22:7797. https://doi.org/10.3748/wjg.v22.i34.7797 CrossRefPubMedPubMedCentral

29.

Mousa OY, Shah R, Hajar N, Landas SK (2015) Periampullary and pancreatic metastases of renal cell carcinoma: an underdiagnosed event. World J Oncol 6:378–380. https://doi.org/10.14740/wjon911w CrossRefPubMedPubMedCentral

30.

Hirshberg Foundation For Pancreatic Cancer Research (2019) Prognosis. https://pancreatic.org/pancreatic-cancer/about-the-pancreas/prognosis/. Accessed 16 Jul 2019

31.

Schwarz L, Sauvanet A, Regenet N et al (2014) Long-term survival after pancreatic resection for renal cell carcinoma metastasis. Ann Surg Oncol 21:4007–4013. https://doi.org/10.1245/s10434-014-3821-4 CrossRefPubMed

32.

Konstantinidis IT, Dursun A, Zheng H et al (2010) Metastatic tumors in the pancreas in the modern era. J Am Coll Surg 211:749–753. https://doi.org/10.1016/j.jamcollsurg.2010.08.017 CrossRefPubMedPubMedCentral

33.

Chua TC, Petrushnko W, Mittal A et al (2016) Pancreatic metastasectomy—an analysis of survival outcomes and prognostic factors. J Gastrointest Surg 20:1188–1193. https://doi.org/10.1007/s11605-016-3106-2 CrossRefPubMed

34.

Deutsch GB, Flaherty DC, Kirchoff DD et al (2017) Association of surgical treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965–2014: relevance of surgical cure in the era of modern systemic therapy. JAMA Surg 152:672–678. https://doi.org/10.1001/jamasurg.2017.0459 CrossRefPubMedPubMedCentral

35.

Lane BR, Kattan MW (2008) Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 35:613–625. https://doi.org/10.1016/j.ucl.2008.07.003 CrossRefPubMed

36.

Bai X, Fisher DE, Flaherty KT (2019) Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-019-0204-6 CrossRefPubMedPubMedCentral

37.

Shimizu Y, Iguchi T, Tamada S et al (2018) Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer. Mol Clin Oncol. https://doi.org/10.3892/mco.2018.1614 CrossRefPubMedPubMedCentral

38.

Grassi P, Doucet L, Giglione P et al (2016) Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis. PLoS ONE 11:e0151662. https://doi.org/10.1371/journal.pone.0151662 CrossRefPubMedPubMedCentral

39.

McNichols DW, Segura JW, DeWeerd JH (1981) Renal cell carcinoma: long-term survival and late recurrence. J Urol 126:17–23. https://doi.org/10.1016/S0022-5347(17)54359-1 CrossRefPubMed

40.

Grassi P, Verzoni E, Mariani L et al (2013) Prognostic role of pancreatic metastases from renal cell carcinoma: results from an italian center. Clin Genitourin Cancer 11:484–488. https://doi.org/10.1016/j.clgc.2013.04.022 CrossRefPubMed

41.

Dreicer R (2009) Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther. https://doi.org/10.2147/OTT.S4052 CrossRefPubMedPubMedCentral

42.

Ishiyama R, Ishihara H, Kondo T et al (2019) Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. Vivo (Brooklyn) 33:2153–2160. https://doi.org/10.21873/invivo.11717 CrossRef

43.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124. https://doi.org/10.1056/NEJMoa065044 CrossRefPubMed

44.

Ghosn M, Eid R, Hamada E et al (2019) OSSMAR: an observational study to describe the use of sunitinib in real-life practice for the treatment of metastatic renal cell carcinoma. J Glob Oncol. https://doi.org/10.1200/JGO.18.00238 CrossRefPubMedPubMedCentral

45.

Ollila DW, Essner R, Wanek LA, Morton DL (1996) Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131(975–9):979–980

Title: Curative-intent pancreas resection for pancreatic metastases: surgical and oncological results
Authors: Sophia Chikhladze
Ann-Kathrin Lederer
Christian M. Kühlbrey
Julian Hipp
Olivia Sick
Stefan Fichtner-Feigl
Uwe A. Wittel
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Nephrectomy
Kidney Cancer
Metastasis
Melanoma
Pancreatectomy
Melanoma
Kidney Cancer
Nephrectomy
Kidney Cancer
Nephrectomy
Published in: Clinical & Experimental Metastasis / Issue 2/2020
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-020-10029-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

The utility of the “Glowing Head” mouse for breast cancer metastasis research

A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence

Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1

Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition

Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation

Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer